公司动态 - Catalyst Pharmaceuticals 公司总裁兼首席执行官 Richard J Daly 及其他管理层成员将参加 2024 年 10 月 7 日举行的 BofA Securities CNS Therapeutics 虚拟会议 [1] - 会议时间为 2024 年 10 月 7 日 9:50 am ET 网络直播链接可在公司官网投资者部分获取 回放将至少保留 30 天 [2] 公司概况 - Catalyst Pharmaceuticals 是一家致力于改善罕见疾病患者生活的生物制药公司 专注于引进 商业化和开发创新疗法 [3] - 公司在美国有稳固的业务 同时积极寻求通过战略合作伙伴关系扩大全球商业版图 总部位于佛罗里达州 Coral Gables 被福布斯 2024 年评为美国最成功的小盘股公司之一 [3]

NEW YORK, Sept. 30, 2024 /PRNewswire/ -- The Boards of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for October, November, and December 2024, as summarized in the charts below: ______________________________________________________________________________ | --- | --- | --- | |--------------|--------------------------------------------------------------------|----------------------------| | Ticker \nFOF | Fund Name \nCohen & Steers Closed-End Opportunity Fund, In ...

NEWTON, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the Bank of America CNS Therapeutics Virtual Conference on Monday, Oct. 7, 2024, at 8:00 a.m. ET. The live webcast may be accessed under the Investors tab on www.acumenpharm.com an ...

LONDON, Sept. 24, 2024 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQB: DDOSF), the distributed denial of service (DDoS) protection specialists, will hold investor calls this week to discuss its unaudited results for the six months ended 30 June 2024. The calls will be led by Corero's CEO, Carl Herberger, and newly appointed CFO, Chris Goulden, and will provide insight into the company's financial performance, strategic initiatives, and outlook for the remainder of the year. Corero's H1 2024 resul ...

NEW YORK, Sept. 12, 2024 /PRNewswire/ -- SUBSCRIBE, a leading operating system for alternative investments serving institutional investors, wealth management firms, and fund managers, announced today that leading real assets investment manager Cohen & Steers (NYSE: CNS) has joined the SUBSCRIBE platform to offer its private real estate strategies. The implementation of a centralized operating system will streamline investment and operational processes for clients in the private wealth channel while expandin ...

NEW YORK, Sept. 10, 2024 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.1 billion as of August 31, 2024, an increase of $3.5 billion from assets under management of $84.6 billion at July 31, 2024. The increase was due to market appreciation of $3.7 billion and net inflows of $8 million, partially offset by distributions of $152 million. Assets Under Management (unaudited) | --- | --- | --- | --- | --- | --- | |------------------------------|------- ...

文章核心观点 Corero Network Security宣布在智利与NovaRed、Vista Group International Ltd（VGL）和GreyMatter签署三项新战略伙伴协议，标志其在拉美市场扩张的重要里程碑，还与GreyMatter合作和智利电信企业Netline达成重要交易，体现其拓展拉美业务及提供服务的决心 [1][5][6] 合作方情况 - NovaRed是拉美领先的网络安全公司，提供全面网络安全服务和解决方案，在阿根廷、巴西、智利和西班牙设有办事处，能处理复杂网络安全挑战 [2] - Vista Group International Ltd（VGL）是电影行业软件解决方案全球领导者，产品涵盖电影业务各方面，在全球有强大影响力，与Corero合作助其拓展媒体和娱乐行业 [3] - GreyMatter是智利科技公司，专注数字转型和软件开发，提供定制软件、移动应用开发等服务，能满足客户特定需求，与Corero合作增强组织数字韧性 [4] Corero Network Security情况 - 是分布式拒绝服务（DDoS）防护专家，提供自动检测和防护解决方案及网络可见性、分析和报告工具，保护复杂环境免受DDoS威胁，确保互联网服务可用性 [6] - 在美国马萨诸塞州马尔伯勒和英国爱丁堡设有运营中心，总部位于伦敦，在伦敦证券交易所AIM市场和美国OTCQB市场上市 [6]

NEW YORK, Aug. 19, 2024 /PRNewswire/ -- Cohen & Steers, Inc.'s (NYSE: CNS) Board of Directors has appointed Lisa Dolly as a director of the company. Ms. Dolly has also been appointed as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. Ms. Dolly is the former Chief Executive Officer of Pershing LLC, a subsidiary of The Bank of New York Mellon Corporation. Ms. Dolly's career spanned over 30 years at Pershing, including over two decades in seni ...

Plus' CNSide leptomeningeal metastases (LM) FORSEE trial met key primary and secondary endpoints CNSide more than doubled the diagnostic sensitivity vs. gold standard cerebral spinal fluid (CSF) cytology and influenced clinical management decisions in over 90% of LM cases AUSTIN, Texas, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for centra ...

Respect-LM dosing shows continued feasibility and safety of up to 44 mCi of intrathecal Rhenium (186Re) Obisbemeda High absorbed radiation doses, mean circulating tumor cell reductions, and median overall survival of 12 months continue to show clinical promise AUSTIN, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous sy ...